Our experts leveraged enormous amounts of
tumor profiling data to identify the validated therapies that are most likely to be effective against this subtype of NSCLC.
Not exact matches
Data generated by the working group, which includes molecular
profiling of over 10,000
tumors across 33
tumor types as well as a series of results on immune -
tumor interaction and response mechanisms, will provide rich characterizations of the relationship between
tumors and the immune microenvironment and its impact on patient outcomes.
To develop the methodology, the group analyzed the molecular
profiles of human embryonic stem cells and compared them with
data for 12,000 samples of 33 different
tumor types held by The Cancer Genome Atlas (TCGA), a U.S. public database.
«The TCGA
data enabled us to
profile and analyze DNA, RNA, and methylation from over 200
tumors, and it made the discovery of these rare alterations possible.»